We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.31 | -0.77% | 39.70 | 40.005 | 39.675 | 39.97 | 934,410 | 15:57:58 |
From Jul 2021 to Jul 2024
By Mary de Wet
The U.S. Food and Drug Administration said Monday that it has approved Apretude, a drug by GlaxoSmithKline unit Viiv to reduce the risk of sexually acquired HIV.
Apretude is the first injectable pre-exposure prophylaxis for the virus that causes AIDS, the agency said.
"This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option," said Dr. Debra Birnkrant, director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research.
At-risk adults and adolescents weighing at least 77 pounds can use Apretude, the FDA said.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
December 20, 2021 16:59 ET (21:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
